Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 67

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017

Summary

According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2017'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

The report 'Placenta Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 3 and 3 respectively. Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion and Retinopathy.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

- The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects

- The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Pipeline Review, H2 2017

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview 6
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment 13
Assessment by Mechanism of Action 13
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development 18
Alteogen Inc 18
Chengdu Kanghong Pharmaceuticals Group Co Ltd 18
Formycon AG 18
Lupin Ltd 19
Regeneron Pharmaceuticals Inc 20
ThromboGenics NV 20
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles 22
(aflibercept + nesvacumab) - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
aflibercept - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
aflibercept biosimilar - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
aflibercept biosimilar - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
aflibercept biosimilar - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
aflibercept SR - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
conbercept - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
SL-186 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
SL-188 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
THR-317 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ziv-aflibercept - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products 52
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products 53
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones 54
Featured News & Press Releases 54
Aug 30, 2017: Bayer to showcase latest Ophthalmology research at EURETINA 2017 54
May 24, 2017: ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting in Budapest, Hungary 55
May 09, 2017: The first UK trial comparing intravitreal aflibercept and laser for proliferative diabetic retinopathy reports at ARVO 2017 56
Jan 17, 2017: ONCURIOUS Announces European Commission Confirmed Orphan Medicinal Product Designation for TB-403 for Medulloblastoma 57
Jan 10, 2017: ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema 58
Sep 28, 2016: Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS 58
Jun 08, 2016: NICE draft recommendation on the use of aflibercept (EYLEA) for management of branch retinal vein occlusion goes against Royal College of Ophthalmologists' guidance 59
May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection 60
May 02, 2016: Oncurious NV, BioInvent and NMTRC Initiating Phase I/IIa Study with TB-403 for the Treatment of Medulloblastoma 61
Mar 15, 2016: BioInvent and Oncurious Partner with US Research Consortium to Accelerate Phase I/IIa Trial of TB-403 62
Mar 01, 2016: Aflibercept in myopic choroidal neovascularization: Added benefit not proven 62
Feb 29, 2016: Formycon discloses details on second pipeline product - FYB203 is a biosimilar for Eylea (aflibercept) 63
Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 64
Oct 30, 2015: Bayer Receives EU Approval for EYLEA for the Treatment of Visual Impairment Secondary to Myopic Choroidal Neovascularization 64
Sep 25, 2015: Bayer's Eye Drug Recommended for EU Approval in Fifth Indication 65
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 66
Disclaimer 67

List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Pipeline by Alteogen Inc, H2 2017 18
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H2 2017 18
Pipeline by Formycon AG, H2 2017 19
Pipeline by Lupin Ltd, H2 2017 19
Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 20
Pipeline by ThromboGenics NV, H2 2017 21
Dormant Projects, H2 2017 52
Discontinued Products, H2 2017 53

List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 13
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16
  • United States Biobanking Market Report 2018
    Published: 22-Feb-2018        Price: US 3800 Onwards        Pages: 108
    In this report, the United States Biobanking market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate ......
  • Global Label-free Array Systems Market Professional Survey Report 2018
    Published: 21-Feb-2018        Price: US 3500 Onwards        Pages: 101
    This report studies Label-free Array Systems in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Agilent Technologies - Attana - Biacore - ForteBio -......
  • Global Prepacked Chromatography Columns Sales Market Report 2018
    Published: 20-Feb-2018        Price: US 4000 Onwards        Pages: 108
    In this report, the global Prepacked Chromatography Columns market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Prepacked Chromatography Columns for these regions, from 2013 to 2025 (forecast), covering - United States - China......
  • 2018-2025 Laser Capture Microdissection Report on Global and United States Market, Status and Forecast, by Players, Types and Applications
    Published: 20-Feb-2018        Price: US 3600 Onwards        Pages: 129
    Summary This report studies the Laser Capture Microdissection market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the Laser Capture Microdissection market by product type and application/end industries. The global Laser Capture Microdissection market is valued at XX million USD in 2017 and is expected to reach XX m......
  • Flow Cytometry Market by Technology (Cell & Bead-based), Product & Services (Analyzer, Sorter, Reagents), Application (Research (Cell Analysis), Clinical (Cancer, HIV)), End User (Academia, Research Institute, Hospital) - Global Forecast to 2022
    Published: 20-Feb-2018        Price: US 5650 Onwards        Pages: 202
    “The global flow cytometry market is projected to grow at a CAGR of 7.8%.” The global flow cytometry market is projected to reach USD 4.79 billion by 2022 from USD 3.29 billion in 2017, growing at a CAGR of 7.8% from 2017 to 2022. The key factors driving the growth of this market include the continuous technological advancements in the field of flow cytometry, increasing incidence and prevalence of target diseases (such as HIV/AIDS and cancer), and growing......
  • C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 60
    C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or High Affinity Interleukin 8 Receptor B or IL8 Receptor Type 2 or CD182 or CXCR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 2 - Pipeline Review, outlays comprehensive information on the C-X-C Chemokine Receptor Type 2 (CDw128b or GRO/MGSA Receptor or ......
  • C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 104
    C-X-C Chemokine Receptor Type 4 (FB22 or Fusin or HM89 or LCR1 or Leukocyte Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide Associated Protein 3 or Stromal Cell Derived Factor 1 Receptor or NPYRL or CD184 or CXCR4) - C-X-C chemokine receptor type 4 or CD184 is a protein encoded by the CXCR4 gene. It is a receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation, extr......
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 46
    According to the recently published report 'Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 st......
  • Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 3500 Onwards        Pages: 79
    Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) pipeline Target constitutes close to 25 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs